Involving collaborative team of clinical and medical technology innovators with operations based in St. Louis, MO and in Dublin, Ireland, Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. Potential implications include earlier prediction of adverse events, optimizing treatment options, and overall better patient disease management. Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space with the objectivebeing that these tests become standard of care, having application across a wide range of indications that include: lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Potential implications include earlier prediction of adverse events, optimizing treatment options, and overall better patient disease management.
